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ABSTRACT 
Foot-and-mouth disease is an acute and highly contagious viral infectious disease. Although the foot and mouth 
disease vaccine has been applied in some parts of the world since the beginning of the 20th century, the current 
epidemic of foot and mouth disease in the world is still serious and constitutes an obstacle to the trade of animal and 
animal products in the world. The porcine pseudorabies virus gene deletion strain PRV TK-/ gE-/ LacZ +, which is 
constructed by our laboratory, has the advantages of good safety, large capacity and high recombination effi  ciency. In 
this study, the artifi cial O-type foot-and-mouth disease P1 gene as an antigen gene, UbiP1 fused with ubiquitin (Ub) 
as another antigen gene to enhance cellular immunity, and then shRNA designed for FMD 3B gene and porcine IFN- 
[gamma] with antiviral and immune-regulatory eff ects. The two functional genes were constructed in turn to construct 
a transfer vector with four functional genes. The transfer vector was transfected into TK-/ gE- / LacZ+ cells with PRV 
deletion vector, and the plasmids were purifi ed and identifi ed. The recombinant pseudorabies virus, which contains 
the six functional genes of P1 gene, UbiP1, shRNA and IFN-γ, was obtained, which laid the foundation for further 
construction of new genetically engineered vaccine.
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1. Introduction
1.1. The basic characteristics of foot and mouth disease
1.1.1 Basic concept of foot and mouth disease virus
Foot-and-month disease (FMD) is an acute and severe infectious disease caused by foot and mouth disease virus 
(FMDV) infection. The disease is widely distributed in the world. The outbreak often creates huge economic losses. The 
development of new genetically engineered vaccines has attracted much attention because of the potential danger of 
inactivation of inactivated inoculum and virulence.
1.1.2 Biological characteristics of foot and mouth disease virus
Foot and mouth disease virus is spherical, positive icosahedral structure, diameter 20-25nm; no capsule, sensitive 
to acid and alkali, foot and mouth disease virus particles from the capsid and viral nucleic acid composition, the shell 
by 60 asymmetric subunits, each sub- unit contains one molecule of VP1, VP2, VP3 and VP4, where VP4 is located 
inside the virus particles. FMDV belongs to the small RNA virus family, and there are seven serotypes, namely, O, A, 
C, SAT 1, SAT 2, SAT 3 and Asia type (Rodriguez and Grubman, 2009), with no cross-reactivity between serotypes (Lu 
Chengping, 2005), the virus of this feature, to its quarantine, epidemic prevention has brought great diffi  culties.
The FMDV genome is an infectious single stranded RNA with a size of about 8.5 kb. There is only one open reading 
frame (ORF), each with a noncoding region (NCR). The open reading frame is fi rst translated as a polyprotein, cleaved 
by protease into mature structures and nonstructural proteins as well as some intermediates. FMDV genome P1 region 
encoding structural protein, P12A precursor in the formation of 3C protease by VP4-VP2, VP3 and VP1 composed of 
the original body. 5 protoplasts form a pentamer, twelve pentamers assembled into RNA containing pre-viral particles or 
lack of RNA empty capsid. In the infected cells, FMDV 3C protease gene encoding protein can catalyze the processing 
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of P12A precursor capsid protein VP0, VP1, VP3, these three proteins can interact to form 5S original body, a virus 
particle structure of the components, the formation of virus-like particles, such virus-free particles without viral nucleic 
acids, have the same immunogenicity as the whole virus.
1.1.3 Foot and mouth disease virus hazards
FMDV is mainly infected with cloven-hoofed species such as pigs, cattle, sheep, goats and buffalo. Many wild 
cloven-like species may also be susceptible to infection, in which camels are proven to be susceptible to foot and mouth 
disease (Larska et al., 2009). Due to infection of foot and mouth disease and sick animal mouth, tongue, lips, hoof, 
breast and other parts of the blisters, ulceration and the formation of rotten spots. Foot and mouth disease incidence 
of almost 100%, the disease once the outbreak, can quickly evolve into biological disasters, directly by the major and 
even devastating blow to the animal husbandry and its related industries. In order to control the spread of the disease, 
the general action is to directly destroy a large number of animals, such a measure not only cannot fundamentally solve 
the epidemic often lead to serious public health problems, causing social panic. Foot and mouth disease outbreak of the 
destructive power will also spread to other industries, such as foreign exports were forced to close, the epidemic area 
was tightly blocked, tourism blocked, such as last April in South Korea outbreak of FMD was the national spread of the 
state, so that the Korean epidemic prevention authorities into a state of emergency. According to the degree of harm of 
foot and mouth disease, the World Organization for Animal Health (FMO) classifi ed foot and mouth disease as a class A 
animal infectious disease, and the Ministry of Agriculture classifi ed foot and mouth disease as a class of animal diseases 
and classifi ed foot and mouth disease virus as a class of animal pathogenic microorganisms.
1.2. The purpose and signifi cance of this experimental study
Pseudorabies and foot and mouth disease is a serious harm to the global pig industry, two major infectious diseases, 
respectively, caused by pseudorabies virus and foot and mouth disease virus. PRV mainly caused pig reproductive 
disorders, with the large-scale development of China’s pig industry, pig pseudorabies epidemic spread trend, and to 
the pig industry brought huge losses. Foot and mouth disease is a common animal and animal disease, acute infectious 
diseases, because of its highly infectious, and the traditional inactivated vaccine in the production process inactivation 
does not completely cause the virus to escape the factory and the risk of foot and mouth disease, foot and mouth disease 
genetic engineering vaccine research is highly valued.
In this study, the porcine IFN-γ gene, the shRNA located in the FMDV 3B region and the two FMDV antigen genes 
P1-UbP1 were inserted into the transfer vector PIECMV, and then the pseudorabies deletion strain PRV TK-/ gE-/ 
LacZ+ was co-transfected, and the U gene of the O-type foot-and-mouth disease antigen gene and the Ubi-P1 gene 
fused with the ubiquitin gene were obtained by the method of plaque screening, and the porcine IFN- [gamma] gene was 
expressed and the O- 3B segment of the RNAi eff ect, to together to achieve the ultimate antiviral eff ect.
2. Experimental materials
2.1. Strains, strains, vectors and plasmids
Pseudorabies attenuated vaccine strain PRVTK-/ gE-/ LacZ+ is constructed by the State Key Laboratory of 
Agricultural Microbiology. The mutant strain lacked 205 bp of the PRVEa strain TK gene and inserted into the LacZ 
expression cassette in the gE coding region, resulting in a deletion of the gE inactivated gene.
The engineering bacteria DH5a and XL-gold were used in this laboratory.
Vector PIECMV by the experimental Ma Rui master graduate students to build.
PUC57pansUbiP12A by the Shanghai Chun Chun company synthesis.
PCAsIFNgsiF by the laboratory Hao Genxi graduate students to build.
PCApansUbiP12AsiF by the laboratory Hao Genxi graduate students to build.
Porcine kidney passage cells PK-15 and African green monkey kidney cells Vero were purchased from China 
Collections.
2.2. Major drugs and reagents
Newborn bovine serum (NCS) was purchased from Hangzhou Sijiqing Material Co., Ltd., before use inactivated by 
56 ℃ 30min.
The DMEM powder for cell culture is GIBCO products.
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Ampicillin (Amp), fetal bovine serum are Invitrogen products.
Various restriction enzymes, ligase, Taq enzyme, DNA Marker are Dalian Bao biological company products.
DNA Recycling Kit is TaKaRa products.
The plasmid is small and a large number of preparation kits are OMEGA products.
Liposome Transfection Kit LIPOFECTIN2000 and serum-free medium OPTI-MEM are products of Invitrogen.
2.3. Main medium and preparation
LB liquid medium: tryptone 10.0g, yeast extract 5.0g, NaCl10.0g, dissolved in ddH20, completely dissolved with 
5mol / LNaOH adjusted to pH 7.0-7.2, constant volume to 1000.0mL, 15 pounds high pressure steam sterilization under 
20min, room temperature preservation.
LB solid culture medium: agar powder was added to the LB liquid medium which had not yet been sterilized to a 
fi nal concentration of 1.5% and autoclaved for 20 min. The temperature of the medium to be reduced to about 50 ℃, 
add the appropriate antibiotics, paving plate. After the medium was solidifi ed, it was kept at 4°C for storage.
DMEM basal culture medium (for conventional cell culture): 13.5g of DMEM powder (Gibic, USA) was dissolved 
in 950 mL of DMH, 3.7 g of NaHCO3 was added, adjusted to pH to 6.8-7.0 with 1 mol /L HCl, ML, 0.22μm fi lter 
sterilization, after storage at room temperature to save spare.
DMEM cell growth solution: 10% of the inactivated newborn bovine serum, 100 μg / mL penicillin, 100 μg / mL 
streptomycin and 4 °C were added to the DMEM basal medium.
DMEM cell maintenance solution: 1% -3% of newborn bovine serum, 100 μg / mL penicillin, 100 μg / mL 
streptomycin, and 4 °C were added to the DMEM medium.
Cell digestion: NaCl 8.0g, KCl 0.2g, Na2HPO4 1.15g, KH2PO4 0.2g, trypsin 2.5g, followed by dissolved in 
900.0mLddH2O, to be completely dissolved, fi xed to 1000.0mL, 0.22μm fi lter bacteria, sub-installed after -20 ℃ save 
reserve.
2.4. Buff er and its preparation
TAE (50 x): 242.0 g Tris base, 57.1 mL glacial acetic acid, 100.0 mL 0.5 mol / LEDTA (pH 8.0), plus ddH2O 
volume to 1000.0 ml.
PBS Buff er: NaCl 8g, KCl 0.2g, Na2HPO4 1.42g, KH2PO4 0.27g dissolved in 800.0mLddH2O, to be completely 
dissolved, add concentrated HCl to adjust the pH to 7.4, constant volume to 1000.0mL, high temperature autoclave 
room temperature save.
10% SDS: Weigh 10g of high purity SDS in 80mLddH2O, dissolve at 68 ℃, add concentrated HCl to adjust the pH 
to 7.2, set to 100.0mL, at room temperature.
0.5 M EDTA: Weigh 186.1g Na2EDTA. 2H2O dissolved in 800.0mLddH2O, stir well, add NaOH to adjust the pH 
to 8.0, constant volume to 1000.0mL, high temperature autoclave after storage at room temperature.
2.5. Other solutions
TEN: 100.0 mol / L NaOH, 10.0 mol / LTris-Cl, 1.0 mol / LEDTA (pH 8.0)
LCM: 30 mol / L (DMSO) 6.0 mmol / L [beta]-MoracPtoethnael, 0.5% NP-40, 125.0 mol / L KCI
Plaque Screening PCR Sample Cell Lysis Solution: 0.5% SDS, 100.0 mmol / L NaCl, 10.0 mmol / L Tris-CL, 1.0 
mmol / LEDTA, 0.25 mg / mL Protease K.
2.6. Oligonucleotide primers
The oligonucleotide primers used in this experiment PCR are shown in Table 1.
Table 1. Oligonucleotide primers used in this study
Number Sequence Uses
R primer
F primer
5- AGCTTTGCGTGACTTTGTGTTTTTC- 3’
5- GCAGGGGGCTGTTTCATATACTGAT- 3’
Identifi cation of positive 
recombinants
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3 Experimental methods
3.1 Construction strategy of transfer vector PIECMVUbiP1P1SiFIFNγ
The construction process of the recombinant transfer vector PIECMVUbiP1P1SiFIFNγ is shown in Fig. 4
Figure 4: Transfer vector PIECMVUbiP1P1SiFIFNγ Construction process
Fig. 4: Building process of PIECMVUbiP1P1SiFIFNγ
3.1.1 Restriction endonuclease digestion
When the digested product was used for detection only, 1 μL of plasmid DNA was added and the corresponding 
restriction enzyme reaction buff er was added. After the addition, the restriction enzyme was added and the mixture 
was homogenized and placed in a 37 °C water bath for 3 hours. If the enzyme is used for the recovery of the 
product, according to the actual situation can increase the amount of plasmid to expand the digestion reaction 
system.
3.1.2 Digestion of the product by agarose gel electrophoresis
Preparation of 0.8% agarose gel (gel concentration should be adjusted according to the size of the target band, if 
the large fragment is low concentration of agarose gel): 20mLddH2O into the 400μL (50 ×) TAE, then add 0.16g 
agarose, heated to completely dissolved, slightly cooled and added to the amount of EB. Gel into the glue tank, 
if the bubble with a comb away, plug the comb, waiting for the gel cooling solidifi cation. Pull out the comb and 
place the gel in an electrophoresis tank with 1 x TAE electrophoresis buff er to ensure that the buff er is drowned. 
Then 1.5-3 μL of the enzyme digest was mixed with a trace 6 × loading buff er and added to the sample wells 
while taking about 2 μL of DNA marker as a control. Electrophoresis at 100-120V. When the bromophenol blue 
electrophoresis to gel 2/3, you can end the electrophoresis. Remove the gel in the gel imaging system to take 
pictures and save the photos.
3.1.3 Recovery of the digested product
The digested product was digested by agarose gel electrophoresis. After identifi cation, the target bands were cut 
under long-wave UV lamp. The DNA fragments were recovered by agarose gel DNA recovery kit (see the kit for 
specifi c recovery methods). The recycling process is as follows:
(1) The cut the target DNA band into the 1.5mL centrifuge tube. (2) Add 600μL of LCI, 50 ℃ water bath for 
10min, turn the centrifuge tube to fully dissolve. (3) The previous step of the solution added to the adsorption 
column, room temperature. (4) Add 600μLPW solution, wait 12000r / min after centrifugation 60min, discard the 
waste; (5) Add again 600μLPW liquid, 12000r / min centrifugal 60sec. (6) 12000r / min centrifugal 2min, open 
the lid for 5min. (7) discard the collection tube, the adsorption column into the centrifuge tube, hanging drop 30-
50μLEB eluent (or ddH2O), 37 ℃ incubator for 5min. (8) 12000r / min centrifugation 2min collection of DNA 
solution, centrifuge tube marker preservation.
3.1.4 Dephosphorylation of the recovered product
In the case of molecular cloning, we need to dephosphorylate the carrier in order to prevent the self-ligating of the 
carrier prepared by the single enzyme digestion during the ligation. The specifi c steps: recovery of 34μL ddH2O in 
50μL system by adding 2μL CIAP, 4μLBuff er placed in 37 ℃ reaction 30min after adding 1μLCIAP placed at 50 
℃ reaction 15min, with the kit for liquid recovery dissolved 20μL ddH2O, gel test.
3.1.5 Enzyme-linked reaction of the target gene with the vector
The recovered DNA fragment was ligated with the vector by T4 DNA ligase, and the enzyme system was prepared 
according to the instructions of T4 DNA ligase provided by Dalian Bao Bioengineering Co., Ltd., as shown in 
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Table 2.
Table 2. Target gene and vector enzyme system
Reaction system Volume (μL)
Carrier
Target gene
T4 DNA Ligase(2~5U／ μL)
10×T4 DNA Ligase Buff er
ddH2O
Total
1
4
1
2
12
20
Placed at 16 °C or 4 °C overnight.
2.7. Preparation of competent cells, plasmid transformation, plasmid preparation and 
purifi cation
3.2.1 Preparation of Escherichia coli competent cells (calcium chloride method)
A single colony was picked from the Escherichia coli DH5α plate and seeded in 2 mL of LB liquid medium at 37 °C 
for 200 r / min shaking under shaking overnight at 1: 100 and transferred to a 50 ml L₂ saline solution. 3-4h, the bacteria 
were transferred to a sterile pre-cooled 50 ml polypropylene centrifuge tube under sterile conditions, placed on ice for 
30 min, centrifuged at 4 h 4000 r / min for 10 min. Discard the supernatant, the centrifuge tube inverted 1min so that 
the residual culture fl ow. Add 10ml ice pre-cooling of 0.1mol/ LCaCl2 re-suspended precipitation, ice bath for 30min, 
4 ℃ 4000r/min centrifugal 10min. Discard the supernatant and add 2 mL of 0.1 mol/L CaCl2 pre-cooled with ice to re-
suspend. Suspended competent cells can be used immediately for transformation. Such as preservation, you need to add 
sterile glycerol to the fi nal concentration of 15%, sub-installed 0.1ml/ tube, -80 ℃ refrigerator to save spare.
3.2.2 Transformation of plasmids
The incubation of the vector with cDNA or DNA gene fragment was mixed with 100μL of competent cells, the ice 
bath was 30min; the bath was heated at 42 ℃ for 90sec; ice bath for 2min; if the plasmid was transformed, 30 ~ 50μL 
antibiotic LB plate; if the conversion of the connection, then add 0.4mL 37 ℃ preheated LB medium, 37 ℃ shaking 
culture 45min; 5000r / min centrifugal 3min, discarded 450μL supernatant, the remaining part of the direct coating Cloth 
containing the corresponding antibiotic LB plate, 37 ℃ culture 12 ~ 16h, the emergence of transformation of colonies.
3.2.3 Identifi cation of positive plasmids
The transformed colonies were picked and seeded in 4 mL of LB liquid medium containing the corresponding 
resistance. Cultured overnight at 37 °C. Plasmid DNA was prepared in small amounts. The recombinant plasmid was 
identifi ed by digestion with suitable restriction endonucleases, agarose gel electrophoresis, EB staining and UV lamp 
observation. In addition, positive plasmids can be further identifi ed by sequencing.
Construction of recombinant virus expressing the FMDV antigen gene P1, ubiquitin protein and antigen P1 fusion 
gene Ubi- P1, RNA interference gene shRNA and interferon gene IFN-γ with PRV as vector
3.3.1 Cell culture, cryopreservation and resuscitation
(1) Cell culture: sterile stage will have grown into a single layer of cell culture fl ask tilted culture medium, washed 
with PBS 1-2 times, add 1mL trypsin 37 ℃ digestion for several minutes, discarded trypsin , add fresh growth liquid 
blowing scattered, according to 1: 3 or 1: 4 pass.
(2) Cell cryopreservation: sterile stage will grow into a single layer of cells with trypsin digestion, discard the 
trypsin, with a small amount of cell cryopreservation (100mL bottle frozen 1-2 tube) Cells, about 1.5 mL per tube in 
the cell cryopreservation tube. Before going to 4 ℃ for 40min-1h, -80 ℃ overnight into the liquid nitrogen tank can 
be stored for several years (or -80 ℃ can save 1-3 months). (10% of serum for 1 case of serum + 1 part of DMSO) and 
70% DMEM + 20% serum + 10% DMSO)
(3) Cell resuscitation: the water bath pre-adjusted to 37 ℃, the growth fluid added to the cell bottle and 37 ℃ 
preheating, and then from the liquid nitrogen tank (or -80 ℃ refrigerator) to remove a tube of frozen cells, the cells were 
quickly melted, and the cell fl uid was transferred into the cell bottle in a sterile platform. The incubation was carried out 
in a 5% CO2 incubator at 37 °C and the fresh growth fl uid (preheated) was continued for 6 hours. )
3.3.2 PRV TK- / gE- / LacZ + Genomic DNA extraction
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The PRV attenuated strain TK- / gE- / LacZ + was inoculated into PK-15 cells grown in monolayer, cultured at 
37 °C to 80% of cells. The cells were stripped from the wall of the flask by blowing with a straw, 4°C 8000 r/min 
centrifugation for 15 min to collect cells. The cell pellet was re-suspended in cell lysate LCM to cell lysis, ice bath for 
5-10min, after adding trichlorotrifl uoroethane extraction, shake 5min, 4 ℃ 3000r / min centrifugal 10min, absorb the 
supernatant in another clean Centrifuge tube, then add trichlorotrifl uoroethane extraction time, shake 5min, 4 ℃ 3000r 
/ min centrifugal 10min, take the supernatant, 4 ℃ 8000r / min centrifugal 10min, take the supernatant, add 5% -45% 
(10% of the volume of supernatant added), equilibrated on an electronic balance, centrifuged at 26,000 r / min for 2 
h, carefully discarded supernatant, the pellet was resuspended in TEN buff er, 10% SDS to the fi nal concentration of 
0.5%, room temperature for 30min, add the same amount of saturated phenol, gently shake about 10min, 10000r / min 
centrifugal 10min, the supernatant in another centrifuge tube, with the same volume of phenol: chloroform: isoamyl 
alcohol (25: 24: 1) twice, take the supernatant by adding 2 times the volume of absolute ethanol, mixed with -20 ℃ 3h 
or overnight, at 4 ℃ 10000r / min centrifugal 20min, discard the supernatant, 70% Ethanol washed precipitate, dried at 
room temperature, dissolved in an appropriate amount of RNaseTE, set 37 ℃ 1h, and fi nally stored at -20 ℃ standby.
3.3.3 Liposome-mediated co-transfection
Using liposome-mediated method according to their kit instructions. The cells were cultured in 24-well cell culture 
plates. The cells were cultured for 4 hours before transfection, and the cells were grown to 40% to 60%. At the time of 
transfection, two 1.5 mL sterile Eppendorf tubes were administered, 1 to 2 μg of transfer plasmid, 1 to 2 μg of genome 
and 50 μL of serum-free medium OPTI-MEM, tube B was added to 3 μL of LIPOFECTIN Reagent and 50 μL of serum-
free medium OPTI-MEM was incubated at room temperature for 5 min. Subsequently, the reagent in tube B was added 
to tube A and allowed to run at room temperature for 20 min. During the 20 min course of the mixture, the medium 
in the 24-well culture plate was discarded and the cells were washed once with serum-free DMEM. The mixture was 
added to the cell monolayer, incubated in a 5% CO2 incubator at 37 °C for 6 h, and then the liquid on the cell culture 
was discarded and the culture medium was added to the cell culture.
The co-transfected product with cytopathic eff ect was repeatedly freeze-thawed three times for 10-fold dilution. The 
virus solution of 10-4-10-6 dilution was taken 400 μL of the PK-15 cells and incubated at 37 ° C for 1 h. The culture 
broth was washed and washed three times with PBS (pH 7.4). Each well covered 2.5 mL of low melting agarose and 
incubated at 37 ° C in CO2 incubator until blank (About 48h), the extraction of a single plaque in 200 μL maintenance 
solution, -20 ℃ repeated freeze-thaw 2 to 3 times, inoculated in PK-15 cells have grown into a single layer of 24-well 
cell culture plate to be After the cell disease, the IFN-γ gene was amplifi ed by PCR, and the positive recombinants were 
subjected to the next plaque assay until 100% purifi ed recombinant virus was obtained.
3.3.4 Identifi cation with PCR template treatment
The template process is as follows:
(1) 24-well plate has been infected cells repeatedly freeze-thawed 2 times, each hole to absorb 200μL supernatant 
virus solution. (2) 10 μL of 10% SDS, 10 μL of 0.5 molLEDTA, 1.3 μL of protease k at 50 ° C for 1 h or at 37 ° C for 6 
h or more (overnight). (3) add the same volume (220μL) phenol: chloroform: isoamyl alcohol extraction time, 12000r 
/ min centrifugal 10min, take supernatant plus 1/10 volume 3MNaAc (PH5.2) and 2 times the volume of anhydrous 
ethanol, -20 ℃ precipitation more than 30min. (4) 12000r / min centrifugal 10min, discard the supernatant, precipitate 
with 500μL 70% ethanol wash once, 12000r / min centrifugal 10min, discard the supernatant, drying, each tube by 
adding 20μL ddH2O dissolved.
3.3.5 Recombinant virus PCR identifi cation
The PCR products were amplifi ed by PCR with 0.8% agarose gel. After the electrophoresis, the gel samples were 
observed and prepared by gel imaging system. Screening of positive recombinants. The PCR amplification system 
conditions for FM-γ gene of foot-and-mouth disease virus are shown in Table 5 and Table 6.
Table 3. reaction system of identifi cation of recombinant virus by PCR
Reaction system Volume (μL) Remarks
DNA template 10 10 × PCR buff er Ingredients
10×PCR buff er 5 Tris-HCI(PH8.3)100mmol/ L ,KCI500 mmol/L
dNTP Mixture 2 MgCl215 mmol/L
F primer 2.5 DNTP Mixture Ingredients: 2.5 mmol / L, in the presence of pH 7.2-9.0 Na 
salt aqueous solution.R primer 2.5
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RTaq enzyme
0.5 F primer and R primer by Shanghai Bioengineering Company:
ddH2O 27.5 Nmol were: 4.1 and 4.5, respectively.
Total 50 RTaq enzyme: 5U / μL.
Table 4. Recombinant virus PCR identifi cation reaction conditions
PCR process Temperature (°C) Time Cycle number
Pre-degeneration
Transsexual
Annealing 
Extend 
Extended again 
End 
94
94
55
72
72
4
3min
1min
45s
45s
10min
forever
} A total of 30 cycles
After the reaction, the PCR product was subjected to 0.8% agarose gel electrophoresis. After gel electrophoresis, gel 
pictures were observed and prepared by gel imaging system.
3. Results and Analysis
3.1. Construction of transfer plasmid PIECMVUbiP1
The UbiP12A gene was digested by restriction endonuclease BamHI, SalI and ScaI, and the UbiP12A gene was 
ligated into PIECMV by restriction endonuclease BglII and XhoI. The obtained transfer plasmid PIECMVUbiP1 
was consistent with the expected result by BamHI digestion, indicating that the transfer plasmid PIECMVUbiP1 was 
successfully constructed.
Figure 1. Identification of Recombinant Plasmid PIECMVUbiP1
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3.2. Construction of Transferring Plasmid PIECMVUbiP1P1
The P12A gene was digested by restriction endonuclease BglII, and the plasmid P12A was digested by restriction 
endonuclease BamH, and the P12A gene was ligated into the vector PIECMVUbiP1. The resulting transfer plasmid 
PIECMVUbiP1P1 was detected by XhoI and it was judged whether the orientation of the P12A gene was consistent 
with that of the promoter. The results were consistent with the expectation that the transfer plasmid PIECMVUbiP1P1 
was successfully constructed.
Figure 2. Recombinant plasmid PIECMVUbiP1P1 digestion
3.3. Construction of Transferring Plasmid PIECMVUbiP1P1SiFIFNγ
The sIFNgsiF gene was obtained by digesting the plasmid pCAsIFNgsiF with the restriction enzymes SalI, ScaI and 
HindIII. The sIFNgsiF gene was ligated into the vector PIECMVUbiP1P1 by restriction endonuclease SalI and HindIII 
to construct the transfer plasmid PIECMVUbiP1P1SiFIFNγ. The results showed that the UbiP12A gene, P12A gene and 
sIFNgsiF gene were successfully cloned into the vector (P <0.05). The recombinant plasmid PIECMVUbiP1P1SiFIFNγ 
was identified by restriction endonuclease digestion. The results showed that the UbiP12A gene, P12A gene and 
sIFNgsiF gene were successfully cloned into the vector PIECMV, the transfer vector PIECMVUbiP1P1SiFIFNγ was 
successfully constructed and the results of restriction enzyme digestion were shown in Fig. 8 below:
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Figure 3. Identification of Recombinant Plasmid PIECMVUbiP1P1SiFIFNγ
3.4. Co-transfection products were identifi ed by the third generation PCR
The transfected product was transfected into cells fi lled with monolayer cells. The cells were harvested for the third 
generation of the cells. The virus genome was extracted and a pair of primers F primer and R primer were designed 
according to the nucleotide sequence. The recombinant virus IFN- γ gene was fragmented and the PCR product was 
electrophoresed by 0.8% agarose gel. The results showed that the gene fragment of 716bp was amplified with the 
expected size (716bp) (as shown in Fig. 9). Indicating that the successful transfection, there can be stable proliferation 
of the positive recombinant virus, followed by plaque purifi cation experiments.
Figure 4. PCR product identification of the third generation genome of the transfected product
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3.5. Purifi cation and PCR identifi cation of recombinant virus
3.5.1 Formation of plaques
After 48 hours of co-transfection, the cells were infected and the transfected product was harvested. After 10 days 
of dilution, the virus solution with 10-2-10-7 dilution was inoculated into 6 wells of monolayer PK-15 cells plate, the 
adsorption of low melting point agarose 37 ℃ carbon dioxide incubator culture 2d, the visible macroscopic spot, which 
in the 10-5 dilution formed the number of plaques suitable for easy selection of plaques (as shown in Figure 10 ).
Figure 5. Plaque Photo
3.5.2 Screening of the fi rst round of plaques on PK-15 cells
Twenty-four plaques were picked up in the plaques formed at the dilutions of 10-4, 10-5 and 10-6 to carry out 
recombinant virus amplifi cation in 80% of PK-15 covered with monolayer 24-well plates, poison. The PCR results of 
the fi rst round of plaque screening of the recombinant virus were shown in Fig. 11. Select the positive recombinant 
virus, the next round of the blank spot screening.
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4. Discussion
4.1. The construction of the carrier
In the construction of the carrier, in order to improve the efficiency of the connection and the accuracy of the 
connection we can through the following aspects to cleverly design the experiment: (1) with the use of the same 
enzyme. When the vector and the plasmid containing the sub-cloned fragment do not contain the same restriction site 
and contain the same coenzyme site that cleaves the complementary cohesive ends, we can use the same enzyme to 
obtain the fragment and vector containing the complementary sticky end used for connection (2). The dephosphorylation 
of the carrier. When the carrier used to ligate the subcloned fragment is treated with only one endonuclease, in order 
to prevent the carrier from self-dephosphorylation, it is necessary to reduce the possibility of carrier self-linking in the 
ligation reaction, fragment connection effi  ciency. (3) Identifi cation of the connection direction. When the vector and 
the target fragment were digested only after the production of a sticky end, we can cleverly select the endonuclease, 
digestion and identifi cation of the target fragment into the direction of whether and the vector promoter in the same 
direction (4). The temperature and time when the reaction is connected. Most of the ligation reaction conditions were 
16 ℃ overnight. Since the transfer plasmid was relatively large in this experiment, the diffi  culty of construction was 
correspondingly large, especially the number of times of connection failure. Therefore, after adjusting the condition of 
a series of reactions, Etc. We can also set the connection reaction temperature to 4 °C, the time can be controlled within 
the range of 8-48 hours.
4.2. Subculture of cells
PK-15 and Vero cells used in this study have good growth and proliferation ability, and can be infi nitely passaged, 
but in order to get the morphology and activity are very good cells, cell passage details is particularly critical.
Like most cell lines, PK-15 and Vero cells were fi rst washed 2-3 times with PBS buff er before subculturing, and the 
appropriate amount of trypsin was placed in a 37 °C incubator. The cells were incubated with the appropriate amount 
of cell culture medium. Under the microscope to see 1-3 cells for the dispersion so far, and then the ratio of about 1: 3 
sub-packaging culture. But the diff erence between the two cell passage processes, as most of the diff erent types of cell 
passage process, is the diff erence between trypsin digestion processes. When the cell is not well digested, there will 
be cells adherent growth, uneven distribution, when the cell digestion time is too long easy to aging, poor shape, low 
activity. And cell digestion is largely dependent on the amount of trypsin and digestion time, when the amount of trypsin 
added too much, the cells are easy to large pieces from the bottle wall off  the lumps, so trypsin cannot evenly distributed 
on the cell surface, resulting in even if the blow cannot be dispersed into a single cell, in this case, increase the digestion 
time is necessary, but too long will cause excessive cell membrane digestion, cell activity decreased or even cracked. So 
the digestion process of trypsin addition and digestion time for diff erent types of cells must have a good grasp in order 
to cultivate the morphology and activity are very good cells.
4.3. Plaque screening experiment
4.3.1 Selection of plaque screening cells
Because of the genetically engineered vaccine against porcine O-type foot and mouth disease recombinant 
pseudorabies virus, the most representative of which is the role of pigs, for these reasons, for such recombinant virus 
plaque screening and a series of experiments is the most commonly used PK-15 cells, a large number of experimental 
results show that the selection of such cells on the general reorganization of the virus screening is no side eff ects, so this 
study was directly transfected positive recombinant virus directly selected with PK-15 cells screening. At the same time, 
taking into account the construction of recombinant virus containing γ interferon gene, and PK-15 cells containing α, β, 
γ interferon gene coding region, may regulate the recombinant virus interferon gene, including a series of expression, 
regulation , immune and other physiological processes, the inhibition of the growth of the virus itself is not conducive 
to the acquisition of positive recombinant virus, so at the same time use another very commonly used Vero cells for the 
study of recombinant virus screening.
From the plaque screening experiment and the viral genome PCR amplifi cation results can be seen that interferon 
gamma did not aff ect the growth of PK-15 cells, so the use of the cells as a carrier can theoretically be used for the 
screening of the recombinant virus.
4.3.2 Eff ects of RNA interference on plaque screening results
Experiments have shown that the addition of exogenous synthetic siRNA molecules to mammalian cells can induce 
specifi c RNA interference.
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4.3.3 Eff ects of Interferon - γ on Plaque Screening Results
Studies have shown that cattle γ-interferon (rBoIFN-γ) gene and VP1 gene recombination in foot and mouth disease 
vaccine, can be integrated in Pichia pastoris co-expression, and the expression of a high concentration of the product 
to the supernatant, can signifi cantly improve the body fl uids and cellular immune responses induced in mice (Shi et al., 
2006). 
This study fi rst demonstrates that the FMDV vaccine, which incorporates the gamma interferon gene, enhances the 
body’s immune response, and secondly suggests that the interferon-gamma gene does not aff ect yeast and fungi and 
mammals Normal growth activity, followed by FMDV vaccine in the process of screening the formation of the plaque 
state is very good, so γ-interferon gene does not interfere with the recombinant genome foot and mouth disease vaccine 
itself, but the plaque from the PCR results can be seen in the PK15 cells the screening on the Vero cells cannot extract 
the genome of the cells, so the recombinant virus γ-interferon gene on its host cell growth is aff ected, but also to be 
further verifi ed by subsequent experiments.
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